See more : SaveLend Group AB (publ) (YIELD.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Sight Sciences, Inc. (SGHT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sight Sciences, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- The Karnataka Bank Limited (KTKBANK.NS) Income Statement Analysis – Financial Results
- R R Kabel Limited (RRKABEL.BO) Income Statement Analysis – Financial Results
- H&R Block, Inc. (0HOB.L) Income Statement Analysis – Financial Results
- Tesgas S.A. (TSG.WA) Income Statement Analysis – Financial Results
- Fredun Pharmaceuticals Limited (FREDUN.BO) Income Statement Analysis – Financial Results
Sight Sciences, Inc. (SGHT)
About Sight Sciences, Inc.
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 81.06M | 71.33M | 48.96M | 27.64M | 23.35M | 7.53M |
| Cost of Revenue | 11.88M | 12.36M | 8.61M | 9.21M | 6.54M | 2.34M |
| Gross Profit | 69.18M | 58.97M | 40.35M | 18.43M | 16.80M | 5.19M |
| Gross Profit Ratio | 85.34% | 82.67% | 82.41% | 66.68% | 71.97% | 68.95% |
| Research & Development | 17.56M | 22.86M | 15.63M | 8.87M | 8.12M | 5.43M |
| General & Administrative | 106.79M | 117.47M | 74.09M | 40.95M | 30.92M | 13.06M |
| Selling & Marketing | 2.10M | 2.60M | 2.10M | 800.00K | 1.80M | 1.00M |
| SG&A | 108.89M | 120.07M | 76.19M | 41.75M | 32.72M | 14.06M |
| Other Expenses | 0.00 | 2.23M | -6.93M | -71.00K | -35.00K | 0.00 |
| Operating Expenses | 126.45M | 142.92M | 91.82M | 50.62M | 40.84M | 19.49M |
| Cost & Expenses | 138.33M | 155.29M | 100.43M | 59.83M | 47.39M | 21.83M |
| Interest Income | 0.00 | 4.47M | 4.37M | 30.00K | 174.00K | 1.00K |
| Interest Expense | 5.41M | 4.47M | 4.37M | 2.40M | 1.96M | 0.00 |
| Depreciation & Amortization | 614.00K | 1.25M | 1.20M | 1.12M | 432.00K | 63.00K |
| EBITDA | -49.42M | -80.48M | -57.21M | -31.68M | -23.47M | -14.23M |
| EBITDA Ratio | -60.96% | -114.58% | -119.30% | -114.60% | -101.10% | -189.02% |
| Operating Income | -57.27M | -83.95M | -51.48M | -32.19M | -24.04M | -14.30M |
| Operating Income Ratio | -70.66% | -117.70% | -105.15% | -116.45% | -102.96% | -189.87% |
| Total Other Income/Expenses | 1.84M | -2.24M | -11.29M | -2.44M | -1.82M | 1.00K |
| Income Before Tax | -55.44M | -86.20M | -62.77M | -34.63M | -25.86M | -14.30M |
| Income Before Tax Ratio | -68.39% | -120.84% | -128.22% | -125.30% | -110.76% | -189.85% |
| Income Tax Expense | 110.00K | 47.00K | 188.00K | 61.00K | 8.00K | -6.00K |
| Net Income | -55.55M | -86.24M | -62.96M | -34.69M | -25.87M | -14.29M |
| Net Income Ratio | -68.53% | -120.90% | -128.61% | -125.52% | -110.80% | -189.77% |
| EPS | -1.14 | -1.80 | -1.33 | -0.74 | -0.55 | -0.44 |
| EPS Diluted | -1.14 | -1.80 | -1.33 | -0.74 | -0.55 | -0.44 |
| Weighted Avg Shares Out | 48.63M | 47.85M | 47.50M | 46.77M | 46.77M | 32.20M |
| Weighted Avg Shares Out (Dil) | 48.63M | 47.85M | 47.50M | 46.77M | 46.77M | 32.20M |
Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023
MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced...
Sight Sciences Appoints Matt Link as Chief Commercial Officer
Former NuVasive President helped scale high growth medical device company to over $1 billion in revenue Former NuVasive President helped scale high growth medical device company to over $1 billion in revenue
Sight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference
MENLO PARK, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced...
Sight Sciences: Staying Bullish After Q2 Results Beat
Sight Sciences' Q2 2023 financial performance came in above Wall Street analysts, and SGHT's stock price rose by +7.6% last Friday following its results announcement. SGHT's key markets, glaucoma and dry eye, have addressable markets worth billions of dollars. I...
Sight Sciences, Inc. (SGHT) Q2 2023 Earnings Call Transcript
Sight Sciences, Inc. (NASDAQ:SGHT ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Philip Tailor - Investor Relations Paul Badawi - Co-Founder & Chief Executive Officer Ali Bauerlein - Chief Financial Officer Tom Huang -...
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.50 per share a year ago.
Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
MENLO PARK, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today reported...
Wall Street Analysts Predict a 44.19% Upside in Sight Sciences, Inc. (SGHT): Here's What You Should Know
The mean of analysts' price targets for Sight Sciences, Inc. (SGHT) points to a 44.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an...
Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye
Dry eye has significant negative impact on visual function including reading, driving, workplace productivity, physical functioning, and quality of life, and creates a substantial burden to patients and society in general² Dry eye has significant negative impact on visual function...
All You Need to Know About Sight Sciences, Inc. (SGHT) Rating Upgrade to Buy
Sight Sciences, Inc. (SGHT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Source: https://incomestatements.info
Category: Stock Reports